These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20947707)

  • 21. Emerging drugs for chemotherapy-induced emesis.
    Navari RM; Province PS
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
    Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
    Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on the management of chemotherapy-induced nausea and vomiting.
    Viale PH
    J Infus Nurs; 2006; 29(5):283-92. PubMed ID: 17035890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
    Durand JP; Madelaine I; Scotté F
    Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastrointestinal inflammation plays a critical role in chemotherapy-induced nausea and vomiting.
    Chen W; Zhao Y; Dai Y; Nie K
    Eur J Pharmacol; 2022 Dec; 936():175379. PubMed ID: 36356927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CINV: still troubling patients after all these years.
    Aapro M
    Support Care Cancer; 2018 Mar; 26(Suppl 1):5-9. PubMed ID: 29556808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies.
    Adel N
    Am J Manag Care; 2017 Sep; 23(14 Suppl):S259-S265. PubMed ID: 28978206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses.
    Clark-Snow R; Affronti ML; Rittenberg CN
    Support Care Cancer; 2018 Feb; 26(2):557-564. PubMed ID: 28871358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Opin Drug Saf; 2016; 15(3):343-56. PubMed ID: 26699406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of chemotherapy-induced nausea and vomiting.
    Van Ryckeghem F; Van Belle S
    Acta Clin Belg; 2010; 65(5):305-10. PubMed ID: 21128556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting.
    Burmeister H; Aebi S; Studer C; Fey MF; Gautschi O
    Support Care Cancer; 2012 Jan; 20(1):141-7. PubMed ID: 21234609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of the prevention and management of CINV.
    Natale JJ
    Am J Manag Care; 2018 Oct; 24(18 Suppl):S391-S397. PubMed ID: 30328690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
    Wang XF; Feng Y; Chen Y; Gao BL; Han BH
    Sci Rep; 2014 Apr; 4():4813. PubMed ID: 24770591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
    dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP
    J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
    Jordan K; Kasper C; Schmoll HJ
    Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.